GlaxoSmithkline Pharmaceuticals 

₹2,400
77
+₹40.3+1.71% 今天

統計

當日最高
2,431.8
當日最低
2,357
52週高點
3,515.7
52週低點
2,217.6
成交量
30,162
平均成交量
65,358
市值
406.58B
本益比
38.21
股息殖利率
1.78%
股息
42.72

即將到來

股息

1.78%股息殖利率
Jun 25
₹42
Nov 24
₹12
Jul 24
₹32
Jul 23
₹32
Jul 22
₹60
10年成長
5.32%
5年成長
6.96%
3年成長
9.49%
1年成長
不適用

財報

19May預期
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
下一步
12.29
13.82
15.34
16.87
預期EPS
不適用
實際EPS
不適用

財務

24.89%利潤率
有盈利
2019
2020
2021
2022
2023
2024
74.52B營收
18.55B淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 GLAXO.NSE 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states in adult patients; Flutivate, a skin cream for adults, children and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.
Show more...
執行長
Mr. Bhushan Akshikar
員工
3113
國家
IN
ISIN
INE159A01016

上市

0 Comments

分享你的想法

FAQ

GlaxoSmithkline Pharmaceuticals 今天的股價是多少?
GLAXO.NSE 目前價格為 ₹2,400 INR,過去 24 小時上漲了 +1.71%。在圖表上更密切關注 GlaxoSmithkline Pharmaceuticals 股價表現。
GlaxoSmithkline Pharmaceuticals 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,GlaxoSmithkline Pharmaceuticals 的股票以代號 GLAXO.NSE 進行交易。
GlaxoSmithkline Pharmaceuticals 的股價在上漲嗎?
GLAXO.NSE 股票較上週上漲 +3.58%,本月下跌 -3.73%,過去一年 GlaxoSmithkline Pharmaceuticals 下跌 -10.5%。
GlaxoSmithkline Pharmaceuticals 的市值是多少?
今天 GlaxoSmithkline Pharmaceuticals 的市值為 406.58B
GlaxoSmithkline Pharmaceuticals 下一次財報日期是什麼時候?
GlaxoSmithkline Pharmaceuticals 將於 May 19, 2026 公布下一次財報。
GlaxoSmithkline Pharmaceuticals 上一季度的財報如何?
GLAXO.NSE 上一季度的財報為每股 16.87 INR,預估為 不適用 INR,帶來 不適用 的驚喜。下一季度的預估財報為每股 不適用 INR。
GlaxoSmithkline Pharmaceuticals 去年的營收是多少?
GlaxoSmithkline Pharmaceuticals 去年的營收為 74.52BINR。
GlaxoSmithkline Pharmaceuticals 去年的淨利是多少?
GLAXO.NSE 去年的淨收益為 18.55BINR。
GlaxoSmithkline Pharmaceuticals 會發放股息嗎?
是的,GLAXO.NSE 的股息每 年度 發放一次。每股最新股息為 42 INR。截至今日,股息殖利率(FWD)% 為 1.78%。
GlaxoSmithkline Pharmaceuticals 有多少名員工?
截至 April 10, 2026,公司共有 3,113 名員工。
GlaxoSmithkline Pharmaceuticals 位於哪個產業?
GlaxoSmithkline Pharmaceuticals從事於Health Care產業。
GlaxoSmithkline Pharmaceuticals 何時完成拆股?
GlaxoSmithkline Pharmaceuticals 上次拆股發生於 September 11, 2018,比例為 2:1。
GlaxoSmithkline Pharmaceuticals 的總部在哪裡?
GlaxoSmithkline Pharmaceuticals 的總部位於 IN 的 Mumbai。